Glucose deprivation increases nuclear DNA repair protein Ku and resistance to radiation induced oxidative stress in human cancer cells

Cell Biochemistry and Function

Volumn 27, Issue 2, 2009, Pages 93-101

  Li, Jie ^a   Ayene, Roashan ^a   Ward, Kathleen M ^a   Dayanandam, Eswarkumar ^a   Ayene, Iraimoudi S ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Glucose deprivation; Glutathione; GRP78; Ku protein; Oxidative stress; Tumor microenvironment

Indexed keywords

GLUCOSE; GLUCOSE REGULATED PROTEIN 78; GLUTATHIONE; KU ANTIGEN; HELICASE; THIOL DERIVATIVE; XRCC5 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL LEVEL; CELL MEMBRANE RESISTANCE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA REPAIR; GAMMA RADIATION; GLUCOSE BLOOD LEVEL; GLUCOSE DEPRIVATION; HUMAN; HUMAN CELL; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION RESPONSE; RADIOSENSITIVITY; ANIMAL; DNA DAMAGE; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA HELICASES; DNA REPAIR; GLUCOSE; HUMANS; NEOPLASMS; OXIDATIVE STRESS; RADIATION TOLERANCE; SULFHYDRYL COMPOUNDS;

EID: 63149084191     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1541     Document Type: Article

References (49)

1. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3: 177-182.
2. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-1416.
3. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res 2000; 60: 6201-6207.
4. Blaszyk H, Hartmann A, Cunningham JM, et al. A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer 2000; 89: 32-38.
5. Pirollo KF, Bouker KB, Chang EH. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000; 11: 419-432.
6. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996; 40: 197-223.
7. Cartron PF, Juin P, Oliver L, Meflah K, Vallette FM. Impact of proapoptotic proteins Bax and Bak in tumor progression and response to treatment. Expert Rev Anticancer Ther 2003; 3: 563-570.
8. Kyprianou N, King ED, Bradbury D, Rhee JG. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997; 70: 341-348.
9. Ayene IS, Bernhard EJ, McKenna WG, Muschel RJ, Krisch RE, Koch CJ. DNA as an important target in radiation-induced apoptosis of MYC and MYC plus RAS transfected rat embryo fibroblasts. Int J Radiat Biol 2000; 76: 343-354.
10. Geng L, Walter S, Melian E, Vaughan AT. Transfection of a vector expressing wild-type p53 into cells of two human glioma cell lines enhances radiation toxicity. Radiat Res 1998; 150: 31-37.
11. Minagawa Y, Kigawa J, Itamochi H, et al. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Jpn J Cancer Res 1999; 90: 1373-1379.
12. Kemp LM, Sedgwick SG, Jeggo PA. X-ray sensitive mutants of Chinese hamster ovary cells defective in double-strand break rejoining. Mutat Res 1984; 132: 189-196.
13. Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9: 273-276.
14. Rosenberg E, Taher MM, Kuemmerle NB, Farnsworth J, Valerie K. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res 2001; 61: 764-770.
15. Ayene IS, Ford LP, Koch CJ. Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Mol Cancer Ther 2005; 4: 529-536.
16. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 2002; 62: 6400-6404.
17. Chang M, Shi M, Forman HJ. Exogenous glutathione protects endothelial cells from menadione toxicity. Am J Physiol 1992; 262: L637-643.
18. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000; 60: 143-154.
19. Phimister AJ, Lee MG, Morin D, Buckpitt AR, Plopper CG. Glutathione depletion is a major determinant of inhaled naphthalene respiratory toxicity and naphthalene metabolism in mice. Toxicol Sci 2004; 82: 268-278.
20. Stenius U, Warholm M, Rannug A, Walles S, Lundberg I, Hogberg J. The role of GSH depletion and toxicity in hydroquinone-induced development of enzyme-altered foci. Carcinogenesis 1989; 10: 593-599.
21. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ. Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol 1997; 40: 38-44.
22. Yang Z, Faustino PJ, Andrews PA, et al. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 2000; 46: 255-262.
23. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999; 14: 169-177.
24. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001; 26: 504-510.
25. Wyld L, Tomlinson M, Reed MW, Brown NJ. Aminolaevulinic acid-induced photodynamic therapy: cellular responses to glucose starvation. Br J Cancer 2002; 86: 1343-1347.
26. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 2003; 278: 20915-20924.
27. Shen J, Hughes C, Chao C, et al. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci U S A 1987; 84: 3278-3282.
28. Rao RV, Peel A, Logvinova A, et al. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett 2002; 514: 122-128.
29. Scorrano L, Oakes SA, Opferman JT, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003; 300: 135-139.
30. Harding HP, Calfon M, Urano F, Novoa I, Ron D. Transcriptional and translational control in the mammalian unfolded protein response. Annu Rev Cell Dev Biol 2002; 18: 575-599.
31. Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: 2189-2200.
32. Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10: 2245-2252.
33. Schroeder T, Yuan H, Viglianti BL, et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res 2005; 65: 5163-5171.
34. Becker D, Summerfield S, Gillich S, Sevilla MD. Influence of oxygen on the repair of direct radiation damage to DNA by thiols in model systems. Int J Radiat Biol 1994; 65: 537-548.
35. Michael BD, Prise KM. A multiple-radical model for radiation action on DNA and the dependence of OER on LET. Int J Radiat Biol 1996; 69: 351-358.
36. Prise KM, Folkard M, Davies S, Michael BD. The irradiation of V79 mammalian cells by protons with energies below 2MeV. Part II. Measurement of oxygen enhancement ratios and DNA damage. Int J Radiat Biol 1990; 58: 261-277.
37. Ayene IS, Stamato TD, Mauldin SK, et al. Mutation in the glucose-6-phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress. J Biol Chem 2002; 277: 9929-9935.
38. Ayene IS, Biaglow JE, Kachur AV, Stamato TD, Koch CJ. Mutation in G6PD gene leads to loss of cellular control of protein glutathionylation: Mechanism and implication. J Cell Biochem 2008; 103: 123-135.
39. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006; 66: 632-637.
40. Kato K, Ogura T, Kishimoto A, et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002; 21: 6082-6090.
41. Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004; 208: 143-153.
42. Dong D, Ko B, Baumeister P, et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 2005; 65: 5785-5791.
43. Chatterjee S, Cheng MF, Berger SJ, Berger NA. Induction of M(r) 78,000 glucose-regulated stress protein in poly(adenosine diphosphateribose) polymerase- and nicotinamide adenine dinucleotide-deficient V79 cell lines and its relation to resistance to the topoisomerase II inhibitor etoposide. Cancer Res 1994; 54: 4405-4411.
44. Chatterjee S, Hirota H, Belfi CA, Berger SJ, Berger NA. Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78. Cancer Res 1997; 57: 5112-5116.
45. Chang SH, Barbosa-Tessmann I, Chen C, Kilberg MS, Agarwal A. Glucose deprivation induces heme oxygenase-1 gene expression by a pathway independent of the unfolded protein response. J Biol Chem 2002; 277: 1933-1940.
46. Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003; 22: 7396-7402.
47. Kiani MF, Fenton BM. Inherent cellular differences may explain the dissimilar survival of RIF-1 and KHT tumour cells under aerobic and hypoxic conditions. Int J Radiat Biol 1995; 67: 449-452.
48. Weichselbaum RR, Epstein J, Little JB, Kornblith P. Inherent cellular radiosensitivity of human tumors of varying clinical curability. AJR Am J Roentgenol 1976; 127: 1027-1032.
49. Sanchez-Aguilera A, Montalban C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006; 108: 662-668.